JP2007507519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007507519A5 JP2007507519A5 JP2006534084A JP2006534084A JP2007507519A5 JP 2007507519 A5 JP2007507519 A5 JP 2007507519A5 JP 2006534084 A JP2006534084 A JP 2006534084A JP 2006534084 A JP2006534084 A JP 2006534084A JP 2007507519 A5 JP2007507519 A5 JP 2007507519A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- group
- alkoxy
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 87
- 150000001875 compounds Chemical class 0.000 claims 34
- 125000003545 alkoxy group Chemical group 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 27
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 26
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims 18
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000003282 alkyl amino group Chemical group 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 11
- 125000000304 alkynyl group Chemical group 0.000 claims 11
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 9
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 9
- 125000002252 acyl group Chemical group 0.000 claims 8
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
- 239000003146 anticoagulant agent Substances 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000001544 thienyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 230000000302 ischemic effect Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims 3
- 230000000702 anti-platelet effect Effects 0.000 claims 3
- 229940127219 anticoagulant drug Drugs 0.000 claims 3
- 125000002393 azetidinyl group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- -1 cyano, hydroxy Chemical group 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 2
- 206010002388 Angina unstable Diseases 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 206010038563 Reocclusion Diseases 0.000 claims 1
- 206010050496 Reversible ischaemic neurological deficit Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims 1
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 229940123987 Thromboxane A2 receptor antagonist Drugs 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229940127226 anticholesterol agent Drugs 0.000 claims 1
- 239000003420 antiserotonin agent Substances 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 229940072645 coumadin Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 230000000994 depressogenic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 229940118179 lovenox Drugs 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
- 0 CC(C1*)(C=C(*)N(C2=*)c(cc3)ccc3NC(N[S@@](C3=CC=*=CS3)=CC)=C)C2=CC(F)=C1N(*)* Chemical compound CC(C1*)(C=C(*)N(C2=*)c(cc3)ccc3NC(N[S@@](C3=CC=*=CS3)=CC)=C)C2=CC(F)=C1N(*)* 0.000 description 4
- VQKHLRAHSUCHPU-UHFFFAOYSA-N C/C=S(\c([s]1)ccc1Cl)/NC(Nc(cc1F)ccc1N(C=Cc(c1c2)cc(NC)c2F)C1=O)=O Chemical compound C/C=S(\c([s]1)ccc1Cl)/NC(Nc(cc1F)ccc1N(C=Cc(c1c2)cc(NC)c2F)C1=O)=O VQKHLRAHSUCHPU-UHFFFAOYSA-N 0.000 description 1
- WFFXFESZIHJORJ-UHFFFAOYSA-N CC(NS(c([s]1)ccc1Cl)(=O)=O)=O Chemical compound CC(NS(c([s]1)ccc1Cl)(=O)=O)=O WFFXFESZIHJORJ-UHFFFAOYSA-N 0.000 description 1
- XQFCCCMHSHSTGG-UHFFFAOYSA-N CCc([s]1)ccc1S(NC(Nc(cc1)ccc1N(C=Cc(c1c2)cc(NC)c2F)C1=O)=O)(=O)=O Chemical compound CCc([s]1)ccc1S(NC(Nc(cc1)ccc1N(C=Cc(c1c2)cc(NC)c2F)C1=O)=O)(=O)=O XQFCCCMHSHSTGG-UHFFFAOYSA-N 0.000 description 1
- CNTHSECNYMVVJC-UHFFFAOYSA-N CCc(cc(cc1)N(C=Cc(cc2NC)c3cc2F)C3=O)c1NC(NS(c([s]1)ccc1Cl)(=O)=O)=O Chemical compound CCc(cc(cc1)N(C=Cc(cc2NC)c3cc2F)C3=O)c1NC(NS(c([s]1)ccc1Cl)(=O)=O)=O CNTHSECNYMVVJC-UHFFFAOYSA-N 0.000 description 1
- WLDFNDDGSMZJKJ-UHFFFAOYSA-N CNc(c(F)c1)cc(C=CN2c(cc3)cc(OCC4CC4)c3NC(NS(C3SC(Cl)=CC3)(=O)=O)=O)c1C2=O Chemical compound CNc(c(F)c1)cc(C=CN2c(cc3)cc(OCC4CC4)c3NC(NS(C3SC(Cl)=CC3)(=O)=O)=O)c1C2=O WLDFNDDGSMZJKJ-UHFFFAOYSA-N 0.000 description 1
- HWTAUFHVTRGWHC-UHFFFAOYSA-N CNc(cc(C=CN(c1cnc(NC(NSc([s]2)ccc2Cl)=O)nc1)C1=O)c1c1)c1F Chemical compound CNc(cc(C=CN(c1cnc(NC(NSc([s]2)ccc2Cl)=O)nc1)C1=O)c1c1)c1F HWTAUFHVTRGWHC-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50840203P | 2003-10-03 | 2003-10-03 | |
| US60/508,402 | 2003-10-03 | ||
| PCT/US2004/032104 WO2005035520A1 (en) | 2003-10-03 | 2004-09-29 | Substituted isoquinolinones |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007507519A JP2007507519A (ja) | 2007-03-29 |
| JP2007507519A5 true JP2007507519A5 (enExample) | 2007-11-08 |
| JP4879745B2 JP4879745B2 (ja) | 2012-02-22 |
Family
ID=34434908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006534084A Expired - Fee Related JP4879745B2 (ja) | 2003-10-03 | 2004-09-29 | 置換イソキノリノン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7294635B2 (enExample) |
| EP (1) | EP1667989A4 (enExample) |
| JP (1) | JP4879745B2 (enExample) |
| KR (1) | KR20060113699A (enExample) |
| CN (1) | CN1863789B (enExample) |
| AU (1) | AU2004279809B2 (enExample) |
| CA (1) | CA2539882A1 (enExample) |
| IL (1) | IL174445A (enExample) |
| MX (1) | MXPA06003625A (enExample) |
| WO (1) | WO2005035520A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006039212A2 (en) * | 2004-09-29 | 2006-04-13 | Portola Pharmaceuticals, Inc. | Substituted 2h-1,3-benzoxazin-4(3h)-ones |
| US20080312208A1 (en) * | 2005-07-13 | 2008-12-18 | Astrazeneca Ab | Pyridine Analogues |
| TWI391378B (zh) | 2006-03-16 | 2013-04-01 | Astellas Pharma Inc | 喹啉酮衍生物或其製藥學上可被容許之鹽 |
| CN101511815A (zh) * | 2006-07-04 | 2009-08-19 | 阿斯利康(瑞典)有限公司 | 新型吡啶类似物 |
| WO2008004941A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | New pyridine analogues |
| TW200811133A (en) * | 2006-07-04 | 2008-03-01 | Astrazeneca Ab | New pyridine analogues III 334 |
| US7834023B2 (en) * | 2006-09-20 | 2010-11-16 | Portola Pharmaceuticals, Inc. | Substituted dihydroquinazolines as platelet ADP receptor inhibitors |
| US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| KR101638035B1 (ko) | 2007-01-22 | 2016-07-11 | 지티엑스, 인코포레이티드 | 핵 수용체에 결합하는 물질 |
| WO2008133155A1 (ja) | 2007-04-19 | 2008-11-06 | Astellas Pharma Inc. | 二環式ヘテロ環化合物 |
| KR101509829B1 (ko) * | 2007-05-02 | 2015-04-06 | 포톨라 파마슈티컬스, 인코포레이티드 | 혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법 |
| US20090018166A1 (en) * | 2007-07-13 | 2009-01-15 | Astrazeneca Ab | New Pyridine Analogues X 161 |
| CN103739547B (zh) * | 2014-01-03 | 2015-09-02 | 沈阳药科大学 | 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法 |
| ES2718175T3 (es) * | 2014-12-02 | 2019-06-28 | Lilly Co Eli | Compuestos de 1-oxo-1,2-dihidroisoquinolin-7-il-(tiofen-2-il-5-sustituido)-sulfonamida, formulaciones que contienen esos compuestos, y su uso como inhibidores de AICARFT en el tratamiento de cánceres |
| JP6929792B2 (ja) | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| CN110914256A (zh) | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3847925A (en) * | 1971-07-15 | 1974-11-12 | En Nom Collectif Science Et Ci | Benzenesulfonyl semicarbazides |
| US5314902A (en) * | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
| SE9702774D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| CA2318199A1 (en) | 1998-01-15 | 1999-07-22 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
| WO2001057037A1 (en) * | 2000-02-04 | 2001-08-09 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
| US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
-
2004
- 2004-09-29 KR KR1020067008642A patent/KR20060113699A/ko not_active Ceased
- 2004-09-29 US US10/956,006 patent/US7294635B2/en not_active Expired - Lifetime
- 2004-09-29 JP JP2006534084A patent/JP4879745B2/ja not_active Expired - Fee Related
- 2004-09-29 WO PCT/US2004/032104 patent/WO2005035520A1/en not_active Ceased
- 2004-09-29 CA CA002539882A patent/CA2539882A1/en not_active Abandoned
- 2004-09-29 MX MXPA06003625A patent/MXPA06003625A/es active IP Right Grant
- 2004-09-29 AU AU2004279809A patent/AU2004279809B2/en not_active Ceased
- 2004-09-29 EP EP04785303A patent/EP1667989A4/en not_active Withdrawn
- 2004-09-29 CN CN2004800289444A patent/CN1863789B/zh not_active Expired - Fee Related
-
2006
- 2006-03-21 IL IL174445A patent/IL174445A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008514703A5 (enExample) | ||
| JP2007507551A5 (enExample) | ||
| CA2540214A1 (en) | 2,4-dioxo-3-quinazolinylaryl sulfonylureas | |
| JP2008517983A5 (enExample) | ||
| RU2009110442A (ru) | Конденсированные производные имидазола для лечения нарушений, опосредованных альдостеронсинтазой, и/или 11-бета-гидроксилазой, и/или ароматазой | |
| NO20082389L (no) | 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler | |
| JP2009543867A5 (enExample) | ||
| UY26754A1 (es) | Derivados de la 1, 3, 8, -triaza-spiro (4,5) decan-4-ona | |
| WO2002022592A3 (en) | Substituted urea neuropeptide y y5 receptor antagonists | |
| RU2010110640A (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| JP2008514703A (ja) | 置換２ｈ−１，３−ベンゾオキサジン−４（３ｈ）−オン | |
| RU2009128966A (ru) | Новые производные аминопиримидина в качестве ингибиторов plr1 | |
| RU2007134380A (ru) | Антибактериальные производные пиперидина | |
| CA2668997A1 (en) | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors | |
| GB0128499D0 (en) | Therapeutic agents | |
| JP2007533741A5 (ja) | Ｂａｃｅ阻害剤として有用なピロリジン誘導体 | |
| Pandya et al. | Synthesis and structure–activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: Application of weakly basic sulfoximine group as novel S4 binding element | |
| EP1396487A1 (en) | Phenylpyridine carbonyl piperazine derivative | |
| RU2009127642A (ru) | 1-замещенные производные имидазола и их применение в качестве ингибиторов альдостеронсинтазы | |
| EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| AR038864A1 (es) | Inhibidores pirimidina y piridina biciclicos de la p38 quinasa | |
| ATE397605T1 (de) | Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol | |
| JP2008519087A5 (enExample) | ||
| RU2008152247A (ru) | Производные циннамоил-пиперазина и их применение в качестве антагонистов par-1 | |
| PT1856045E (pt) | Derivados do ácido indol-1-acético que possuem actividade antagonista de pgd2 |